Research HTC

Actively Enrolling Studies

AVA-ITP-401 – Phase IV trial of safety and satisfaction in adults with chronic Immune Thrombocytopenia (ITP) after switching to avatrombopag from eltrombopag or romiplostim. Please visit for more information.

PATH-HHT – Placebo-controlled, double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT). Please visit for more information.

ACTIV-4c – COVID-19 thrombosis prevention trial: post-hospital thromboprophylaxis. Please visit for more information.

Myeloproliferative neoplasms (MPN) – Investigation of the contribution of red blood cell endothelial interactions to bleeding and thrombosis.

Active Studies No Longer Enrolling

GENEr8-1 – Phase III, gene therapy trial for adults with severe hemophilia A. Please visit for more information. 

HOPE-B – Phase III, gene therapy trial for adults with severe or moderately severe hemophilia B. Please visit for more information. 

MOSH Outcomes – An observational study of the natural history of outcomes in hemophiliacs undergoing major orthopedic surgery.

EVE – Randomized, phase III trial of apixaban in preventing secondary cancer related venous thrombosis. Please visit for more information.

Recently Closed Studies

Affinergy 003– Development of a multiplex point-of-care assay to identify patients with venous thromboembolism.

Hokusai Peds VTE – Phase III trial to evaluate the safety and efficacy of edoxaban with standard of care anticoagulant therapy in pediatrics with venous thromboembolism (VTE). Please visit for more information.

A-TREAT – Phase III trial to evaluate antifibrinolytic therapy with tranexamic acid (TXA) in preventing bleeding in cancer patients who are thrombocytopenic. Please visit for more information.

To learn more about our research, inquiries can be sent to: unchtcresearch@med.unc.edu